Phase 3 Study of RLY-2608 + Fulvestrant vs Capivasertib + Fulvestrant as Treatment for Locally Advanced or Metastatic PIK3CA-mutant HR+/HER2- Breast Cancer
Applying to Robert H. Lurie Comprehensive Cancer Center of Northwestern University · Chicago, Illinois
Answer a few short questions to share with the research team.